Self-complementary recombinant adeno-associated virus

Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. Cell 33 —43 [ PubMed ] [ Google Scholar ]. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication.

Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. Chem —90 [ PubMed ] [ Google Scholar ]. Nature —84 [ PubMed ] [ Google Scholar ]. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.

Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 rAAV2 -CFTR vector in adult cystic fibrosis patients: a two-part clinical study. A novel adenovirus—adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome.

Brain Res. Gene transfer by adeno-associated virus vectors into the central nervous system. Neurol —24 [ PubMed ] [ Google Scholar ]. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.

Ther 7 —97 [ PubMed ] [ Google Scholar ]. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.

Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Genet 8 —54 [ PubMed ] [ Google Scholar ]. Neurol —56 [ PubMed ] [ Google Scholar ].

Long-term follow-up after gene therapy for Canavan disease. Repeated delivery of adeno-associated virus vectors to the rabbit airway. Cross-packaging of a single adeno-associated virus AAV type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Biotechnol 23 —28 [ PubMed ] [ Google Scholar ]. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Clades of adeno-associated viruses are widely disseminated in human tissues. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.

Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Res 99 :e3—9 [ PubMed ] [ Google Scholar ]. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain.

Ther 13 —37 [ PubMed ] [ Google Scholar ]. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Mutational analysis of the adeno-associated virus type 2 AAV2 capsid gene and construction of AAV2 vectors with altered tropism. Warrington KH Jr.

Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus.

Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Application of a haematopoetic progenitor cell-targeted adeno-associated viral AAV vector established by selection of an AAV random peptide library on a leukaemia cell line. Vaccines Ther 6 Directed evolution of adeno-associated virus for glioma cell transduction.

Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. AAV ancestral reconstruction library enables selection of broadly infectious viral variants. In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector.

Cell Rep. Efficient and targeted transduction of nonhuman primate liver with systemically delivered optimized AAV3B vectors. Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Role for highly regulated rep gene expression in adeno-associated virus vector production. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.

Novel tools for production and purification of recombinant adenoassociated virus vectors. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Ther 7 —50 [ PubMed ] [ Google Scholar ]. Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins. Cell lines for the production of recombinant adeno-associated virus.

Insect cells as a factory to produce adeno-associated virus type 2 vectors. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells.

Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. In vivo model of adeno-associated virus vector persistence and rescue.

Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Cell Mol. Biol 11 —21 [ PubMed ] [ Google Scholar ]. Lancet —3 [ PubMed ] [ Google Scholar ]. Safety and biological efficacy of an adeno-associated virus vector—cystic fibrosis transmembrane regulator AAV-CFTR in the cystic fibrosis maxillary sinus. Laryngoscope —74 [ PubMed ] [ Google Scholar ]. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.

Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. Genet 24 —61 [ PubMed ] [ Google Scholar ].

Blood —72 [ PubMed ] [ Google Scholar ]. Med 12 —47 [ PubMed ] [ Google Scholar ]. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Long-term safety and efficacy of factor IX gene therapy in hemophilia B. Development of methods for the selective measurement of the single amino acid exchange variant coagulation factor IX Padua.

Methods Clin. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Med —39 [ PubMed ] [ Google Scholar ]. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Efficacy and safety of voretigene neparvovec AAV2-hRPE65v2 in patients with RPEmediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.

Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Metab 97 —44 [ PubMed ] [ Google Scholar ].

Long-term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis. Sustained secretion of human alphaantitrypsin from murine muscle transduced with adeno-associated virus vectors.

Ther 6 —35 [ PubMed ] [ Google Scholar ]. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. Single-dose gene-replacement therapy for spinal muscular atrophy. Keefer E. Jones F. A segment of the Mecp2 promoter is sufficient to drive expression in neurons. GarciaCozar F. Boissier M. Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms. Gene Ther. Levenson J.

Vilaythong A. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Joussemet B. Riviere C. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Nurre E. Montgomery C. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Dailey M. Preparation of rodent hippocampal slice cultures. CSH Protoc. Adeno-associated virus: From defective virus to effective vector.

Blake B. Criswell H. Choi V. Samulski R. Production and characterization of adeno-associated viral vectors. McCown T. Inducible long-term gene expression in brain with adeno-associated virus gene transfer. Passini M. Parente M. Long-term AAV vector gene and protein expression in mouse brain from a small pan-cellular promoter is similar to neural cell promoters.

Wilcox G. Intrathecal morphine in mice: A new technique. Meyer E. Peel A. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors.

Hamby M. Gong Y. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Lingor P. Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Briggs D. Gil A. Proudfoot N. Definition of an efficient synthetic poly A site. Genes Dev. Monahan P. Self-complementary recombinant adeno-associated virus scAAV vectors promote efficient transduction independently of DNA synthesis.

Adeno-associated virus terminal repeat TR mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Xiao X. Brain Res. Yamamura K. Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Moccetti T. Mura A. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain.

McIlwain K. Kenneson A. Hotta A. Pasceri P. Analysis of AAV serotypes 1—9 mediated gene expression and tropism in mice after systemic injection. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Systemic and persistent muscle gene expression in rhesus monkeys with a liver de-targeted adeno-associated virus AAV vector.

Scott LJ. Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro.

Engineering the AAV capsid to optimize vector-host-interactions. Curr Opin Pharmacol. Directed evolution of novel adeno-associated viruses for therapeutic gene delivery. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous.

Sci Transl Med. Controlling AAV tropism in the nervous system with natural and engineered capsids. Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors.

Front Immunol. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front Microbiol. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus.

Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors. Nat Commun. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer.

Optimization of the capsid of recombinant adeno-associated virus 2 AAV2 vectors: the final threshold? PLoS One. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses.

Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Basner-Tschakarjan E, Mingozzi F. Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.

Serotype-specific binding properties and nanoparticle characteristics contribute to the immunogenicity of rAAV1 vectors. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis.

Balakrishnan B, Jayandharan GR. Basic biology of adeno-associated virus AAV vectors used in gene therapy. Curr Gene Ther. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Investig. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. Nonnenmacher M, Weber T. Intracellular transport of recombinant adeno-associated virus vectors. J Innate Immun. CpG-depleted adeno-associated virus vectors evade immune detection.

Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Kotin RM. Large-scale recombinant adeno-associated virus production.

Hum Mol Genet. Clement N, Grieger JC. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Wright JF. Manufacturing and characterizing AAV-based vectors for use in clinical studies.

Interaction of adeno-associated virus Rep78 with p implications in growth inhibition. Can Res. Adeno-associated virus type 2 Rep78 induces apoptosis through caspase activation independently of p OneBac 2. OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1—12 vectors for gene therapy.

Arden E, Metzger JM. Inexpensive, serotype-independent protocol for native and bioengineered recombinant adeno-associated virus purification. J Biol Methods. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells.

A simplified purification protocol for recombinant adeno-associated virus vectors. Production, purification and characterization of adeno-associated vectors.

Ultracentrifugation-free chromatography-mediated large-scale purification of recombinant adeno-associated virus serotype 1 rAAV1 Mol Ther Methods Clin Dev. Comparative analysis of adeno-associated virus capsid stability and dynamics. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.

Lancet Lond, Engl ; — Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2.

Duan D. Systemic delivery of adeno-associated viral vectors. Curr Opin Virol. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet. Recombinant adeno-associated viral integration and genotoxicity: insights from animal models.

Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Adeno-associated virus-based gene therapy for CNS diseases. Adeno-associated virus vectors and neurological gene therapy. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.

J Control Release. Systemic gene delivery to the central nervous system using Adeno-associated virus. Front Mol Neurosci. Selkoe DJ, Hardy J. Acta Neuropathol. Fish KM, Ishikawa K. Advances in gene therapy for heart failure. Greenberg B. Gene therapy for heart failure. J Cardiol. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease CUPID 2 : a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.

Cystic fibrosis gene therapy in the UK and elsewhere. Gene therapy for the treatment of cystic fibrosis. Appl Clin Genet. Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors. Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Journey to the center of the cell: current nanocarrier design strategies targeting biopharmaceuticals to the cytoplasm and nucleus.

Curr Pharm Des. Getting there is half the battle: recent advances in delivering therapeutics. Integr Biol. Alpha 2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6.

Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain.

Gene therapy vectors based on adeno-associated virus type 1. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection.

Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer.

J Biol Chem. Structure of adeno-associated virus serotype 5. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Adeno-associated virus AAV vectors package single-stranded genomes and require host-cell synthesis of the complementary strand for transduction.

However, when the genome is half wild-type size, AAV can package either two copies, or dimeric inverted repeat DNA molecules.